Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $23.14 billion. The enterprise value is $22.72 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 216.75 million shares outstanding. The number of shares has increased by 20.64% in one year.
| Current Share Class | 216.75M |
| Shares Outstanding | 216.75M |
| Shares Change (YoY) | +20.64% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 94.94% |
| Float | 198.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.31 |
| Forward PS | 11.68 |
| PB Ratio | 33.65 |
| P/TBV Ratio | 46.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 27.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.47, with a Debt / Equity ratio of 1.05.
| Current Ratio | 4.47 |
| Quick Ratio | 3.88 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.73 |
Financial Efficiency
Return on equity (ROE) is -294.46% and return on invested capital (ROIC) is -42.30%.
| Return on Equity (ROE) | -294.46% |
| Return on Assets (ROA) | -31.11% |
| Return on Invested Capital (ROIC) | -42.30% |
| Return on Capital Employed (ROCE) | -56.29% |
| Weighted Average Cost of Capital (WACC) | 9.15% |
| Revenue Per Employee | $492,526 |
| Profits Per Employee | -$711,391 |
| Employee Count | 1,664 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.28 |
Taxes
In the past 12 months, Insmed has paid $5.58 million in taxes.
| Income Tax | 5.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +62.13% in the last 52 weeks. The beta is 0.89, so Insmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +62.13% |
| 50-Day Moving Average | 137.33 |
| 200-Day Moving Average | 156.00 |
| Relative Strength Index (RSI) | 33.96 |
| Average Volume (20 Days) | 3,950,394 |
Short Selling Information
The latest short interest is 14.71 million, so 6.79% of the outstanding shares have been sold short.
| Short Interest | 14.71M |
| Short Previous Month | 13.86M |
| Short % of Shares Out | 6.79% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 7.27 |
Income Statement
In the last 12 months, Insmed had revenue of $819.56 million and -$1.18 billion in losses. Loss per share was -$5.70.
| Revenue | 819.56M |
| Gross Profit | 670.48M |
| Operating Income | -965.22M |
| Pretax Income | -1.18B |
| Net Income | -1.18B |
| EBITDA | -949.04M |
| EBIT | -965.22M |
| Loss Per Share | -$5.70 |
Full Income StatementBalance Sheet
The company has $1.22 billion in cash and $742.46 million in debt, with a net cash position of $481.05 million or $2.22 per share.
| Cash & Cash Equivalents | 1.22B |
| Total Debt | 742.46M |
| Net Cash | 481.05M |
| Net Cash Per Share | $2.22 |
| Equity (Book Value) | 704.85M |
| Book Value Per Share | 3.26 |
| Working Capital | 1.25B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$895.66 million and capital expenditures -$25.97 million, giving a free cash flow of -$921.64 million.
| Operating Cash Flow | -895.66M |
| Capital Expenditures | -25.97M |
| Depreciation & Amortization | 16.18M |
| Net Borrowing | -5.02M |
| Free Cash Flow | -921.64M |
| FCF Per Share | -$4.25 |
Full Cash Flow StatementMargins
Gross margin is 81.81%, with operating and profit margins of -117.77% and -144.44%.
| Gross Margin | 81.81% |
| Operating Margin | -117.77% |
| Pretax Margin | -143.76% |
| Profit Margin | -144.44% |
| EBITDA Margin | -115.80% |
| EBIT Margin | -117.77% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.64% |
| Shareholder Yield | -20.64% |
| Earnings Yield | -5.10% |
| FCF Yield | -3.97% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $200.00, which is 87.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $200.00 |
| Price Target Difference | 87.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 44.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 7.82 and a Piotroski F-Score of 4.
| Altman Z-Score | 7.82 |
| Piotroski F-Score | 4 |
